Share：
Share this content in WeChat
X
[Chinese][PDF]93586
• Review •
Progress of Gd-EOB-DTPA in the diagnosis and evaluation of HCC
CAO Liang  LI Rui  ZHANG Qian  LIU Jingni  GUO Shunlin 

Cite this article as: Cao L, Li R, Zhang Q, et al. Progress of Gd-EOB-DTPA in the diagnosis and evaluation of HCC. Chin J Magn Reson Imaging, 2020, 11(10): 943-946. DOI:10.12015/issn.1674-8034.2020.10.028.


[Abstract] gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) has become an important tool for the diagnosis of hepatocellular carcinoma. It can improve the sensitivity and accuracy of hepatocellular carcinoma (HCC) and early HCC, and can reflect the biological characteristics and differentiation of HCC lesions, and provide new guidance for pre- and post-treatment evaluation of HCC. This article reviews the research progress of Gd-EOB-DTPA in the diagnosis and biological characteristics evaluation of HCC.
[Keywords] Gd-EOB-DTPA；hepatocellular carcinoma；magnetic resonance imaging；diagnosis；evaluation

CAO Liang Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

LI Rui Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

ZHANG Qian Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

LIU Jingni Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

GUO Shunlin* Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

*Correspondence to: Guo SL, E-mail: guoshl@lzu.edu.cn

Conflicts of interest   None.

Received  2020-03-10
Accepted  2020-05-21
DOI: 10.12015/issn.1674-8034.2020.10.028
Cite this article as: Cao L, Li R, Zhang Q, et al. Progress of Gd-EOB-DTPA in the diagnosis and evaluation of HCC. Chin J Magn Reson Imaging, 2020, 11(10): 943-946. DOI:10.12015/issn.1674-8034.2020.10.028.

[1]
Jaferian S, Soleymaninejad M, Negahdari B, et al. Stem cell, biomaterials and growth factors therapy for hepatocellular carcinoma. Biomed & Pharmaco, 2017, 88: 1046-1053.
[2]
Joo I, Lee JM. Recent advances in the imaging diagnosis of hepatocellular carcinoma: Value of gadoxetic acid-enhanced MRI. Liver Cancer, 2016, 5(1): 67-87.
[3]
Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology, 2014, 273(1): 30-50.
[4]
Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology, 2015, 275(1): 97-109.
[5]
Imbriaco M, De Luca S, Coppola M, et al. Diagnostic accuracy of Gd-EOB-DTPA for detection hepatocellular carcinoma (HCC): A comparative study with dynamic contrast enhanced magnetic resonance imaging (MRI) and dynamic contrast enhanced computed tomography (CT). Polish J Radiol, 2017, 82: 50-57.
[6]
Semaan S, Vietti VN, Lewis S, et al. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. Eur Radiol, 2020, 30(2): 1020-1030.
[7]
International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology (Baltimore, Md), 2009, 49(2): 658-664.
[8]
Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology, 2011, 261(3): 834-844.
[9]
Kim HD, Lim YS, Han S, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology, 2015, 148(7): 1371-1382.
[10]
Hwang J, Kim YK, Jeong WK, et al. Nonhypervascular hypointense nodules at gadoxetic acid-enhanced MR imaging in chronic liver disease: Diffusion-weighted imaging for characterization. Radiology, 2015, 276(1): 137-146.
[11]
Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut, 2018, 67(9): 1674-1682.
[12]
Lee SA, Lee CH, Jung WY, et al. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magne Reson Imaging, 2011, 29(1): 83-90.
[13]
Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging-correlation with molecular transporters and histopathologic features. Radiology, 2010, 256(3): 817-826.
[14]
Asayama Y, Tajima T, Nishie A, et al. Uptake of Gd-EOB-DTPA by hepatocellular carcinoma: radiologic-pathologic correlation with special reference to bile production. Eur J Radiol, 2011, 80(3): e243-e248.
[15]
Erra P, Puglia M, Ragozzino A, et al. Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review. Radiol Med, 2015, 120(11): 1002-1011.
[16]
Tong HF, Liang HB, Mo ZK, et al. Quantitative analysis of gadoxetic acid-enhanced magnetic resonance imaging predicts histological grade of hepatocellular carcinoma. Clin Imaging, 2017, 43: 9-14.
[17]
Peng Z, Jiang M, Cai H, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma. BMC Cancer, 2016, 16: 625.
[18]
额•图娅，欧阳汉. Gd-EOB-DTPA MRI在监测肝硬化结节多步态癌变早期中的应用进展.磁共振成像, 2019, 10(4): 312-316.
[19]
Inchingolo R, De Gaetano AM, Curione D, et al. Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver. Eur Radiol, 2015, 25(4): 1087-1096.
[20]
覃夏丽，黄仲奎，龙莉玲,等.钆塞酸二钠增强MRI T1 mapping鉴别诊断不典型增生结节及不同分化程度肝细胞癌的价值.中华放射学杂志, 2018, 52(8): 603-607.
[21]
Yoneda N, Matsui O, Kitao A, et al. Benign hepatocellular nodules: Hepatobiliary phase of gadoxetic acid-enhanced MR imaging based on molecular background. Radiographics, 2016, 36(7): 2010-2027.
[22]
Suh YJ, Kim MJ, Choi JY, et al. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. AJR Am J Roentgenol, 2011, 197(1): W44-52.
[23]
Kitao A, Matsui O, Yoneda N, et al. Differentiation between hepatocellular carcinoma showing hyperintensity on the hepatobiliary phase of gadoxetic acid-enhanced MRI and focal nodular hyperplasia by CT and MRI. AJR Am J Roentgenol, 2018, 211(2): 347-357.
[24]
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet (London, England), 2014, 383(9935): 2168-2179.
[25]
Xu J, Igarashi S, Sasaki M, et al. Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Inter, 2012, 32(7): 1156-1164.
[26]
Hwang J, Kim YK, Min JH, et al. Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI. Eur Radiol, 2017, 27(11): 4581-4590.
[27]
Choi SY, Kim YK, Min JH, et al. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging. Eur Radiol, 2018, 28(6): 2549-2560.
[28]
Kim R, Lee JM, Joo I, et al. Differentiation of lipid poor angiomyolipoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Abdominal Imaging, 2015, 40(3): 531-541.
[29]
Fujita N, Nishie A, Kubo Y, et al. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol, 2015, 25(1): 211-220.
[30]
Toyoda H, Kumada T, Tada T, et al. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. Hepatol Int, 2015, 9(1): 84-92.
[31]
Huang M, Liao B, Xu P, et al. Prediction of microvascular invasion in hepatocellular carcinoma: Preoperative Gd-EOB-DTPA-Dynamic enhanced MRI and histopathological correlation. Contrast Media & Molecular Imaging, 2018, 2018: 9674565.
[32]
陈培培，陆健，张涛,等.钆塞酸二钠增强MRI对肝细胞癌微血管侵犯的预测价值.中华放射学杂志, 2019, 53(2): 103-108.
[33]
Ahn SJ, Kim JH, Park SJ, et al. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis. Abdominal Radiol(New York), 2019, 44(2): 539-548.
[34]
Ye Z, Jiang H, Chen J, et al. Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: A prospective study. Chin J Cancer Res, 2019, 31(5): 806-817.
[35]
Yang L, Gu D, Wei J, et al. A radiomics nomogram for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Liver Cancer, 2019, 8(5): 373-386.

PREV Application progresses of intravoxel incoherent motion imaging in heart disease
NEXT Research progress of neoadjuvant radiotherapy and chemotherapy for rectal cancer based on magnetic resonance imaging radiology
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn